EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A 28-Day, Polysomnographic and Subjective Assessment of Vestipitant (15mg/day) for the Treatment of Primary Insomnia in Adult Outpatients
Trial description: This study is a 28-day polysomnographic and subjective assessment of oral Vestipitant 15mg/day for treatment of Primary Insomnia in adults outpatients.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Assessment of objective PSG measure of sleep onset, duration and continuity for wake after persistent sleep onset (WASO1)
Timeframe: Day 27/28
Assessment for wake after sleep onset (WASO) as the mean of PSG recordings obtained on two consecutive nights on Days 27/28
Timeframe: Day 27,28
Secondary outcomes:
Assessment for WASO1 as the mean of PSG recordings obtained on two consecutive nights on Days 1/2.
Timeframe: Day 1/2
Assessment for WASO as the mean of PSG recordings obtained on two consecutive nights on Days 1/2.
Timeframe: Day 1/2
Assessment of objective PSG measure of sleep onset, duration and continuity for latency to persistent sleep (LPS)
Timeframe: Day 1/2 and Day 27/28
Assessment of objective PSG measure of sleep onset, duration and continuity for total sleep time (TST)
Timeframe: Day 1/2 and Day 27/28
Assessment of objective PSG measure of sleep onset, duration and continuity for wake during sleep (WDS)
Timeframe: Day 1/2 and Day 27/28
Assessment of objective PSG measure of sleep onset, duration and continuity for wake after sleep (WAS)
Timeframe: Day 1/2 and Day 27/28
Assessment of objective PSG measure of sleep onset, duration and continuity for number of awakenings during sleep (NAW)
Timeframe: Day 1/2 and Day 27/28
Assessment of subjective sleep assessments as performed by Post-Sleep Questionnaires (PSQs) using Interactive Voice Response System (IVRS) for PSG parameter TST and Sleep onset latency (SOL)
Timeframe: Day 2 (Pre-dose), Day 2 (Inpatient), Day 28 (Post-Dose), Day 35 (Follow-up)
Assessment of subjective sleep assessments as performed by Post-Sleep Questionnaires (PSQs) using Interactive Voice Response System (IVRS) for PSG parameter NAW
Timeframe: Day 2 (Pre-dose), Day 2 (Inpatient), Day 28 (Post-Dose), Day 35 (Follow-up)
Assessment of subjective sleep assessments as performed by participant-rated Insomnia Severity Index (ISI)
Timeframe: Baseline, Day 15, Day 28, Day 42
Number of participants who passed Romberg and Heel-to-toe test for the assessment of motor and cognitive functioning
Timeframe: Day 1 (Visit 2), Day 2 (Visit 3), Day 15 (Visit 6), Day 27 (Visit 7), Day 28 (Visit 8)
Assessment of Motor and cognitive functioning by Digit Symbol Substitution test (DSST)
Timeframe: Day 1 (Visit 2), Day 2 (Visit 3), Day 3 (Visit 4), Day 4 (Visit 5), Day 27 (Visit 7) and Day 28 (Visit 8)
Assessment of Motor and cognitive functioning by Hopkins Verbal Learning Test-Revised (HVLT-R)
Timeframe: Day 2 (Visit 3), Day 4 (Visit 5) and Day 28 (Visit 8)
Interventions:
Enrollment:
161
Primary completion date:
2009-23-09
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Emiliangelo Ratti, David J. Carpenter, Stefano Zamuner, Sofia Fernandes, Lisa Squassante, Heidi Danker-Hopfe, Graeme Archer, Jonathan Robertson, Robert Alexander, David Trist, Emilio Merlo-Pich. Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia. Sleep. 2013;36(12):1823-1830.
Medical condition
Sleep Disorders
Product
vestipitant
Collaborators
GSK
Study date(s)
May 2009 to September 2009
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18 - 64 years
Accepts healthy volunteers
No
- Male and female aged 18-64 years inclusively with Diagnosis of Primary Insomnia according to Diagnostic and Statistical Manual of Mental Disorders –Text Revision (DSM-IV-TR) criteria 307.42
- PSG variables collected during 2consecutive PSG screening nights falling as follows: TST between 240-420 mins inclusive (both nights) - LPS (Latency to Persistent Sleep): mean not less than 20mins, each night not less than 15 mins - WASO (Wake After Sleep Onset): mean not less than 60mins, each night not less than 45mins
- clinically significant Psychiatric and neurological disorders (sleep disorders other than Primary Insomnia, history of alcohol orother substance abuse or dependnce);
- nightshift or rotating shift-work;
Inclusion and exclusion criteria
Inclusion criteria:
- Male and female aged 18-64 years inclusively with Diagnosis of Primary Insomnia according to Diagnostic and Statistical Manual of Mental Disorders –Text Revision (DSM-IV-TR) criteria 307.42
- PSG variables collected during 2consecutive PSG screening nights falling as follows: TST between 240-420 mins inclusive (both nights)
- LPS (Latency to Persistent Sleep): mean not less than 20mins, each night not less than 15 mins
- WASO (Wake After Sleep Onset): mean not less than 60mins, each night not less than 45mins
- Women: non child bearing potential or if child bearing potential agree on Contraceptive Methods listed in Protocol
Exclusion criteria:
- clinically significant Psychiatric and neurological disorders (sleep disorders other than Primary Insomnia, history of alcohol orother substance abuse or dependnce);
- nightshift or rotating shift-work;
- Lifestyle habits in agreement with Protocol requirement: caffeine
- alcohol intake and smoke
- healthy according to GSK criteria
- laboratory and ECG limits set in the Protocol
Trial location(s)
Location
GSK Investigational Site
Magdeburg, Sachsen-Anhalt, Germany, 39112
Status
Study Complete
Location
GSK Investigational Site
Dresden, Sachsen, Germany, 01307
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Schwerin, Mecklenburg-Vorpommern, Germany, 19055
Status
Study Complete
Showing 1 - 6 of 13 Results
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2009-23-09
Actual study completion date
2009-23-09
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website